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OBJECTIVE: Chronic hepatitis B (CHB) affects more
than 300 million people worldwide, resulting in substan-
tial morbidity and mortality from cirrhosis and hepato-
cellular carcinoma. Additionally, healthcare costs and
loss of quality of life are great. Alpha-interferon (IFN)
and lamivudine (LAM) are currently available for the
treatment of CHB. This study estimates the short- and
long-term cost-effectiveness of LAM or IFN compared to
standard CHB therapy (i.e., monitoring and treatment once
disease progresses) from a healthcare payer perspective.
METHODS: A decision tree was designed to estimate
clinical outcomes and costs for each therapy after 1 year.
A Markov model was employed to estimate the long-
term costs and disease progression. A hypothetical cohort
of 100 CHB patients with hepatitis B e antigen was as-
signed to each therapy. Model data were drawn from 4
clinical trials, literature on liver disease progression and
resource utilization. Seroconversion was used as the ef-
fectiveness measure in the short-term model. Life expect-
ancy, quality-adjusted life years (QALYs), and incremen-
tal cost-effectiveness ratios (ICER) were estimated for the
long-term model. RESULTS: In the short-term, the ICER
was higher for IFN than for LAM ($US 26,812 vs. $US
7067 per seroconversion) compared to standard therapy.
Although LAM results in greater quality-adjusted life ex-
pectancy than IFN in the long-term, the ICERs were si-
milar ($2247 vs. $2050 per QALY). The results from the
models were somewhat sensitive to drug efficacy. CON-
CLUSION: Both LAM and IFN are cost-effective alterna-
tives to the standard therapy. Although LAM may be
preferred in the short-term, any advantage it has over
IFN diminishes with time.
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Although the use of pediatric diphtheria, tetanus, and
pertussis vaccine has led to a dramatic decline in pertus-
sis, a resurgence of pertussis has been observed. Alarm-
ingly, pertussis infection among healthcare workers
(HCWs) is now more common than almost all other dis-
eases for which HCWs are routinely vaccinated. Because
of regular contacts with patients, HCWs are at increased
risk for pertussis transmission. The addition of an acellu-
lar pertussis component to the CDC-recommended diph-
theria and tetanus adult booster vaccine is therefore an
essential part of hospital infection control. However, pol-
icy-makers may require evidence that this addition is eco-
nomically justified before endorsing it. OBJECTIVES: To
provide a preliminary assessment of the economic value
of vaccinating all hospital workers. METHODS: A litera-
ture-based decision analysis was developed to project the
impact of hospital staff vaccination on the number of
symptomatic infections and ensuing economic burden.
The model specifically accounts for the savings resulting
from the reduction in symptomatic infections due to per-
tussis exposures following admission of patients with
pertussis. RESULTS: Vaccinating all US hospital workers
(approximately 5,000,000) once every 10 years would re-
sult in over 36,000 infections avoided per decade, of
which 1,450 are projected to require hospitalization. The
number of post-exposure pertussis cases would be reduced
by 5000. Combined, these two benefits would result in
$39.5 million in cost savings, or $7.73 per vaccinated
worker, excluding the cost of vaccine. CONCLUSIONS:
The results of this preliminary analysis suggest that vacci-
nation of hospital staff would result in substantial cost
savings. Policy-makers should not exclude HCWs from
their recommendation considerations until more defini-
tive economic results can be provided.
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The choice of antibiotic for treatment of community-
acquired pneumonia (CAP) is performed without bacteri-
ologic analysis in 100% of cases. Utilization antibiotic
data will help to realize its real tendency and capabilities.
OBJECTIVES: The study purpose was to investigate the
use of antibiotics in correlation with cost-effectiveness in
CAP. METHODS: The study was performed by analyz-
ing 800 files of patients with CAP from out-patient depart-
ments. The diagnosis was based on physical examination,
X-ray and laboratory data. The type of antimicrobial, its
dose, duration of treatment until recovery, and index of
cost-effectiveness were examined in two groups: patients
under 60 years (I) and over 60 years with or without as-
sociated diseases (II). RESULTS: Amino-penicillins were
used in 32% of both groups, macrolides and azalides in
27% (I) and 23% (II), fluoroquinolones, in 22% (I) and
16% (II), aminoglycosides in 8% (I) and in 14% (II) and
others. The most often used combinations were trimetho-
prim/sulfamethoxazole with ampicillin or ciprofloxacin.
Efficiency of antibiotics used was found as following:
azithromycin was 100% in both groups; co-amoxiclav,
